Showing results (41-50 of 107) with videos related to
Sort By:
Pageof 11
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 9, 2024
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6Stephen C Bain, Nicolas Belmar, Søren T Hoff, et al.The American Journal of Cardiology|April 9, 2018
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)Steven P Marso, Michael A Nauck, Tea Monk Fries, et al.JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.Diabetes, Obesity & Metabolism|October 22, 2021
The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trialsEmilie H Zobel, Bernt Johan von Scholten, Tine W Hansen, et al.Kidney International Reports|July 31, 2024
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 TrialKatherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, et al.Kidney International Reports|December 19, 2022
Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER ProgramsDavid Z I Cherney, Samy Hadjadj, Jack Lawson, et al.Cardiovascular Diabetology|August 24, 2023
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysisPeter Rossing, Stephen C Bain, Heidrun Bosch-Traberg, et al.Journal of the National Cancer Institute|May 20, 2004
Familial clustering of Hodgkin lymphoma and multiple sclerosisHenrik Hjalgrim, Søren Rasmussen, Klaus Rostgaard, et al.Diabetes Care|December 28, 2017
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER TrialLaszlo Hegedüs, Steven I Sherman, R Michael Tuttle, et al.Kidney International|February 4, 2023
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placeboKatherine R Tuttle, Heidrun Bosch-Traberg, David Z I Cherney, et al.Pageof 11